Track topics on Twitter Track topics that are important to you
EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s goal is to develop and commercialize therapeutics based on the Company’s scientific expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the progression of cancer and other diseases. The Company’s three clinical product candidates are based on these mechanisms. The Company’s expertise has also led to the identification of new molecules, including new chemical entities derived from 2ME2, as well as new chemical entities associated with multi-kinase inhibition and HDAC inhibition, important targets in the treatment of oncology. Panzem® (2-methoxyestradiol or 2ME2), one of the Company’s two lead drug candidates, is currently being tested as a cancer therapeutic in five Phase 2 clinical trials, and has been granted U.S. Food and Drug Administration (FDA) Orphan Drug designation in three cancer indications, including glioblastoma multiforme (GBM), multiple myeloma, and ovarian cancer. MKC-1, a novel cell cycle inhibitor, is also in Phase 2 clinical trials for cancer. In May 2006, the Company commenced clinical studies with its third clinical-stage compound, ENMD-1198, in patients with advanced cancer. EntreMed is developing compounds that have broad therapeutic and commercial potential in oncology. In order to further advance its commercial objectives, EntreMed may seek strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas.
9640 Medical Center Drive
United States of America
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock ...
EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is f...
EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and antiinflammatory drugs that target disease cells directly and the blood ve...
PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...
Founded in 2008 by the Axis Biotec Brasilâ¢ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....
COOK SIS is sold under various brand names to treat a wide range of conditions including management of dermal wounds and burns, reinforcement of many types of weakened tissue, and treatment of urinary...
We have published hundreds of EntreMed Incorporated news stories on BioPortfolio along with dozens of EntreMed Incorporated Clinical Trials and PubMed Articles about EntreMed Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EntreMed Incorporated Companies in our database. You can also find out about relevant EntreMed Incorporated Drugs and Medications on this site too.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...